The Treatment Of Metabolic Syndrome, Type 2 Diabetes And Heart Disease With Galantamine
A study shows a 25 percent reduction in inflammation-related problems like metabolic syndrome (heart disease and type 2 diabetes) with Galantamine, a drug used for the treatment of Alzheimer's disease. Galantamine will fight with the metabolic syndrome in reducing the risk associated with type 2 diabetes (T2D) and heart diseases.
There are no medications or drugs approved for the treatment of metabolic syndrome. Currently, the healthcare professionals will prescribe the lifestyle changes, treatments, and drugs for the treatment of metabolic syndromes such as hypertension (high blood pressure. BP), high blood sugar (glucose) levels (or type 2 diabetes. T2D), excess body fat and cholesterol levels.
The researchers have found the anti-inflammatory properties of Galantamine, during an experiment on mice models. The researchers say that Galantamine will target the nervous system (which can affect metabolic processes and digestion), including the vagus nerve (which can affect inflammation levels in the body) in the treatment of the metabolic syndrome. The clinical trial for safety is not required as this drug was already approved for the treatment of Alzheimer's disease and the safety of this drug was already established.
The researchers have conducted a double-blind and placebo-controlled trial on about 60 patients with type 2 diabetes (T2D). They divided the participants into two groups. They gave Galantamine to one group of participants and placebo to another group of participants for over 12 weeks. They analyzed the heartbeat, cholesterol levels, insulin resistance, insulin levels, body weight and other markers of inflammation of the participants.
The study shows a marked reduction in the inflammatory markers in the blood, lower insulin levels and lower insulin resistance in the participants under the treatment of Galantamine compared with the participants under the treatment of the placebo. But the study has found an insignificant difference in HDL (good) and LDL (bad) cholesterol levels, body fat and weight changes.
The co-authors of the study were Dr. Yael Tobi Harris, chief of endocrinology, diabetes, and metabolism, the Long Island Jewish Medical Center, New York, and Dr. Valentin A Pavlov, Ph.D., an associate professor, the Feinstein Institute for Medical Research, Manhasset, New York, United States. The study was published in the JCI Insight. Title of the article was "Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial."
Lorcaserin (A Weight Loss Drug) Can Lower High Blood Sugar Levels And Can Increase Insulin Sensitivity In Patients With Type 2 Diabetes
A study at the Rowett Institute, the University of Aberdeen, Aberdeen, Scotland, shows that lorcaserin can cause a significant reduction in blood sugar (glucose) levels in patients with type 2 diabetes (T2D). Currently, lorcaserin is being used for the treatment of obesity. This drug acts by modifying the activity of neurons in the brain which regulate hunger.
This study shows the use of lorcaserin can lower blood sugar (glucose) levels and can increase the insulin sensitivity of the cells in patients with type 2 diabetes (T2D).
This medication will target the brain hormones called pro-opiomelanocortin (POMC) in the brain for regulating the appetite and to provide the therapeutic benefits to patients with type 2 diabetes (T2D). This drug costs around USD $215 for a one-month supply.
The researchers say that this study shows the new treatment option for a patient with type 2 diabetes (T2D). But they say more research was needed with lorcaserin.
The lead author of the study was Professor Lora K Heisler, the Rowett Institute, University of Aberdeen, Aberdeen, Scotland. The study was published in the Molecular Metabolism. Title of the article was "Lorcaserin improves glycemic control via a melanocortin neurocircuit."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.